X4 Pharmaceuticals Inc (XFOR) Stock Price, Quote & News

Company Profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 529 8300

Website: www.x4pharma.com

Address:

61 North Beacon Street, 4th Floor, Boston, United States

isaacwilliams33 Nov. 12 at 10:21 PM

$IMG $AQMS $TGL $SBEV $XFOR all had a decent day today

1 · Reply

Lol_at_ur_bags Nov. 12 at 5:48 PM

$CWD $JBIO $PTPI $XFOR Dude you’re hopping board to board glazing @invinc1ble. At least wipe the glizzy off before posting.

0 · Reply

Pangloss_0589 Nov. 12 at 12:25 PM

$XFOR i listened to the Guggenheim fireside Chat with the New X4 chairman Adam Craig. He seems bullish on the 4ward trial. However he also mentioned it was 1/3 of the way enrolled only, and that was the reason for the management shake up. This mean paula ragan had been lying about enrolment rates and timelines. Looks like too little effort was put on recruiting and too much on finding Whim patients. This strategic error and misleading communication cost her her job. Rightfully so, what a waste of precious time and money.

2 · Reply

GinoGino Nov. 11 at 12:27 AM

$XFOR Completely forgotten by investors, closes red followinga big PT raise! Someday, perhaps!

0 · Reply

JarvisFlow Nov. 10 at 12:09 PM

HC Wainwright & Co. has adjusted their stance on X4 Pharmaceuticals ( $XFOR ), setting the rating to Buy with a target price of 3.5 → 5.

0 · Reply

bowlerhatsftw Nov. 9 at 3:57 PM

$XFOR XFOR

0 · Reply

DARKP00L Nov. 7 at 7:48 PM

$XFOR the market is buzzing about this stock. Expect possible price changes!

0 · Reply

TwongStocks Nov. 7 at 4:19 PM

$XFOR New 13G filing from FMR LLC (Fidelity). Reporting beneficial ownership of 8,499,100 shares as of 10/31, 14.8%. https://www.sec.gov/Archives/edgar/data/1501697/000031506625002923/xslSCHEDULE_13G_X01/primary_doc.xml Per Item 6, most of their ownership is tied in Fidelity Small Cap Growth Fund, which owns 3,386,200 shares. I assume most of FMR's shares are held in other Fidelity funds/ETFs.

0 · Reply

Harold_the_Hedge Nov. 7 at 4:53 AM

$XFOR back to sub 1, this is easy money

1 · Reply

Pope25 Nov. 6 at 3:09 AM

$XFOR how is it going to take them an extra year to enroll an additional 76 participants, and why the expansion? The trial launched, what, 18 months ago? Will be very interested to hear the Guggenheim call next week. Obv the institutions are bought in, but i hope they’re being conservative with timelines and over deliver

1 · Reply

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

Nov 5, 2025, 7:00 AM EST - 9 days ago

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 27, 2025, 7:05 PM EDT - 17 days ago

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

Oct 24, 2025, 12:37 AM EDT - 21 days ago

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

Oct 23, 2025, 4:01 PM EDT - 22 days ago

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Sep 17, 2025, 7:00 AM EDT - 2 months ago

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Aug 15, 2025, 4:05 PM EDT - 3 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2025, 7:00 AM EDT - 3 months ago

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Aug 12, 2025, 7:00 AM EDT - 3 months ago

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Jun 16, 2025, 8:00 AM EDT - 5 months ago

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Jun 10, 2025, 8:00 AM EDT - 5 months ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

May 14, 2025, 4:12 PM EDT - 6 months ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 1, 2025, 12:44 PM EDT - 7 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:01 AM EDT - 7 months ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 28, 2025, 7:16 AM EDT - 7 months ago

Top 3 Health Care Stocks That May Rocket Higher In April

BMY UNH

Apr 24, 2025, 8:03 AM EDT - 7 months ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

Apr 24, 2025, 8:00 AM EDT - 7 months ago

X4 Pharmaceuticals Announces Reverse Stock Split

Apr 23, 2025, 4:05 PM EDT - 7 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2025, 3:02 PM EDT - 8 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 6:01 AM EDT - 8 months ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 8:00 AM EDT - 8 months ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Feb 19, 2025, 7:35 AM EST - 9 months ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 6, 2025, 7:35 AM EST - 10 months ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Jan 24, 2025, 7:36 AM EST - 10 months ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 13, 2025, 7:35 AM EST - 10 months ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Nov 14, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 13, 2024, 9:31 PM EST - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:07 AM EST - 1 year ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:01 AM EST - 1 year ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Oct 24, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Aug 28, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 10, 2024, 9:30 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jul 2, 2024, 6:17 PM EDT - 1 year ago

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jun 27, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 24, 2024, 4:51 AM EDT - 1 year ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR VRNA

May 29, 2024, 4:30 PM EDT - 1 year ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 13, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 9, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 7, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Apr 30, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 29, 2024, 5:02 PM EDT - 1 year ago

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

Apr 29, 2024, 6:37 AM EDT - 1 year ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Apr 29, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

Apr 1, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

Mar 21, 2024, 11:35 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

Dec 13, 2023, 11:43 PM EST - 2 years ago

X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying

Dec 9, 2023, 12:00 PM EST - 2 years ago

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

isaacwilliams33 Nov. 12 at 10:21 PM

$IMG $AQMS $TGL $SBEV $XFOR all had a decent day today

1 · Reply

Lol_at_ur_bags Nov. 12 at 5:48 PM

$CWD $JBIO $PTPI $XFOR Dude you’re hopping board to board glazing @invinc1ble. At least wipe the glizzy off before posting.

0 · Reply

Pangloss_0589 Nov. 12 at 12:25 PM

2 · Reply

GinoGino Nov. 11 at 12:27 AM

$XFOR Completely forgotten by investors, closes red followinga big PT raise! Someday, perhaps!

0 · Reply

JarvisFlow Nov. 10 at 12:09 PM

HC Wainwright & Co. has adjusted their stance on X4 Pharmaceuticals ( $XFOR ), setting the rating to Buy with a target price of 3.5 → 5.

0 · Reply

bowlerhatsftw Nov. 9 at 3:57 PM

$XFOR XFOR

0 · Reply

DARKP00L Nov. 7 at 7:48 PM

$XFOR the market is buzzing about this stock. Expect possible price changes!

0 · Reply

TwongStocks Nov. 7 at 4:19 PM

0 · Reply

Harold_the_Hedge Nov. 7 at 4:53 AM

$XFOR back to sub 1, this is easy money

1 · Reply

Pope25 Nov. 6 at 3:09 AM

1 · Reply

TwongStocks Nov. 5 at 1:41 PM

$XFOR 10-Q filed. Confirms that as of Oct 31, there are 87.4m shares outstanding. https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000150169725000043/xfor-20250930.htm

0 · Reply

TwongStocks Nov. 5 at 12:04 PM

$XFOR X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-reports-third-quarter-2025-financial-results • Cash totaled $122.2 million for the period ended September 30, 2025. On October 27, 2025, the Company completed a public offering with net proceeds of $145.6 million, which management believes will enable the Company to fund its operations into the end of 2028. • Now expected to be able to complete the 4WARD trial, file a potential sNDA for the chronic neutropenia indication, and, if successful, launch mavorixafor in this new indication by the end of 2028.

2 · Reply

TwongStocks Nov. 3 at 9:17 PM

$XFOR Perceptive filed a new 13G https://www.sec.gov/Archives/edgar/data/1501697/000119312525262560/xslSCHEDULE_13G_X01/primary_doc.xml Reporting beneficial ownership of 6,064,680 shares, 7.6%. Per Item 4, their 6,064,680 beneficial ownership consists of 5,913,165 shares and 151,515 warrants.

0 · Reply

TwongStocks Oct. 31 at 9:16 PM

$XFOR Trick or treat! XFOR insiders received stock options. • David Kirske (CFO) 1,552,769 options • Adam Craig (Exec Chairman) 2,329,154 options • John Volpone (President) 2,329,154 options The stock options were granted on August 12, 2025, and were subject to a performance-based vesting condition that was satisfied on October 29, 2025. Exercise price of the options is $1.42.

1 · Reply

Davidwxyz Oct. 31 at 2:08 PM

$XFOR Long from $4 / want it to hold $3.67, Could grind higher / day after day / c & h pattern says $18

0 · Reply

GinoGino Oct. 31 at 2:00 AM

$XFOR Enormous potential here, looking forward to the ER next week. Give the company has addressed cashflow problem, with plenty of cash in the bank now, any positive news on clinical side likely to leader to a substantial spike here.

0 · Reply

mcrotary Oct. 30 at 10:59 PM

$XFOR $5+ from here

0 · Reply

Trading_Means_Freedom Oct. 30 at 2:40 PM

$XFOR This is the VC firm that owns 5MM/6% of the float of $XFOR. Stay long and strong, they know what they're doing!

0 · Reply

TwongStocks Oct. 30 at 10:16 AM

$XFOR Growth Equity/NEA filed an updated 13D last night. https://www.sec.gov/Archives/edgar/data/1501697/000107261325000747/xslSCHEDULE_13D_X01/primary_doc.xml They reported taking part in the recent offering, buying 1 million shares at $2.90. They now own 3,233,744 shares and 1,823,866 pre-funded warrants, for beneficial ownership of 5,057,610 shares, 6.2%.

1 · Reply

Pangloss_0589 Oct. 30 at 9:29 AM

$XFOR the activist fund in our capital, NEA (also the fund that led the CTI BO and brought Craig to X4) has more than doubled its position in the latest share offering (13D/A)

0 · Reply

BioTechChap Oct. 29 at 11:20 AM

$XFOR At last a respectable conference again. Hopefully some color on 4WARD enrollment will be shared.

0 · Reply

SadyK189 Oct. 29 at 4:23 AM

Top Stocks to watch tomorrow 2 / 2: $NOK $XFOR $FGL $CREV $IDAI NOK is trending nicely on daily chart. Key support at 6.3 - 6.60. Next key level to test is 8.8 -9.2. Currently at 7.95 CREV: Looking good on daily chart. 5.25 - 5.55 is acting as key support zone. Next key level to test is 7.35 - 7.60. Currently at 6.60 XFOR is consolidating on 4hours chart and has maintained key support zone of 3.1 - 3.3 nicely so far. Next key level to test is 4.5 - 4.8. Currently at 3.81 IDAI is trending nicely on daily chart. Key support at 3.75 - 4. Next key level to test is 5.4 - 5.75. Currently at 4.75 FGL: Getting up on 4hours chart. Key support at 0.43 - 0.47. Next key level to test is 0.68 - 0.71. Currently at 0.57

0 · Reply

Market Cap	44.15M
Revenue (ttm)	2.56M
Net Income (ttm)	-37.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,462.89%
Debt to Equity Ratio	1.23

Volume	167,255
Avg Vol	951,040
Day's Range	N/A - N/A
Shares Out	11.41M
Stochastic %K	53%
Beta	0.51
Analysts	Strong Sell
Price Target	$8.70